MARKET

PTIXW

PTIXW

PROTAGENIC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5002
0.00
0.00%
Opening 16:00 07/29 EDT
OPEN
--
PREV CLOSE
0.4201
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.7999
52 WEEK LOW
0.2600
MARKET CAP
--
P/E (TTM)
-1.5986
1D
5D
1M
3M
1Y
5Y
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that upon reviewing its investigational new d...
GlobeNewswire · 6d ago
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th \- 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the thre...
ACCESSWIRE · 07/08 15:20
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) ...
GlobeNewswire · 07/06 10:17
BRIEF-Protagenic Says Entered Into At Market Issuance Sales Agreement With B. Riley Securities, EF Hutton
reuters.com · 07/02 22:33
BRIEF-Protagenic Files For Mixed Shelf Of Up To $100 Million
reuters.com · 06/04 21:29
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTIXW. Analyze the recent business situations of PROTAGENIC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About PTIXW
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.

Webull offers kinds of Protagenic Therapeutics Inc stock information, including NASDAQ:PTIXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTIXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTIXW stock methods without spending real money on the virtual paper trading platform.